Latest Period
Q1 2026
Security Snapshot
Oncology Institute, Inc. - Common Stock, par value $0.0001 per share (TOI) Institutional Ownership
CUSIP: 68236X100
13F Institutional Holders and Ownership History from Q3 2021 to Q1 2026
Institutions Reporting
115
Shares (Excl. Options)
38,763,593
Price
$3.07
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- TOI on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 38,763,593
- Total 13F value
- $118,924,902
- Portfolio coverage rank
- 0%
- Share change
- +159,444
- Value change
- -$478,811
- Number of holders
- 115
- Shares outstanding
- 101,268,340
- SEC-reported price per share
- $4.00
- Insider filing price
- $4.00
Latest holder snapshot
5 signals
Issuer context
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- TOI - Oncology Institute, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 68236X100.
- 115 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 116 to 115 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $137,199,596 to $118,924,902.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 115 institutions filings for Q1 2026.
Security key
68236X100
Latest holder period
Q1 2026
13F holders
115
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
TOI full holder history
Oncology Institute, Inc. SEC filings
Oncology Institute, Inc. company facts
Oncology Institute, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 68236X100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
TOI
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Chernett Jorey | 10% | $27,110,730 | 10,115,944 | Chernett Jorey | 13 Mar 2026 | |||
| M33 Growth I L.P. | 4.9% | $15,408,180 | 5,002,656 | M33 Growth I L.P. | 14 May 2026 | |||
| SARIN RAVI YANG | 4.7% | $11,959,434 | 4,109,771 | Ravi Sarin | 26 Mar 2025 |
As of 31 Mar 2026, 115 institutional investors reported holding 38,763,593 shares of Oncology Institute, Inc. - Common Stock, par value $0.0001 per share (TOI). This represents 38% of the company’s total 101,268,340 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
34%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 4.4% | 4,415,867 | +13% | 0% | $13,556,712 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.4% | 3,476,781 | 0% | 0% | $10,673,718 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 3.3% | 3,360,052 | 0% | 0.12% | $10,315,360 |
| Kanen Wealth Management LLC | 2.7% | 2,777,858 | -6.7% | 3.1% | $8,528,024 |
| JOSH ARNOLD INVESTMENT CONSULTANT, LLC | 2.4% | 2,464,359 | +0.18% | 6.5% | $7,565,582 |
| Balyasny Asset Management L.P. | 1.8% | 1,826,370 | -27% | 0.01% | $5,606,956 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 1,757,847 | +12% | 0% | $5,397,829 |
| WEXFORD CAPITAL LP | 1.7% | 1,711,323 | +12% | 0.87% | $5,253,762 |
| CenterBook Partners LP | 1.5% | 1,568,423 | -48% | 0.26% | $4,815,059 |
| STATE STREET CORP | 1.4% | 1,461,454 | +8.1% | 0% | $4,486,664 |
| GOLDMAN SACHS GROUP INC | 1.3% | 1,351,899 | +137% | 0% | $4,150,330 |
| BRC Group Holdings, Inc. | 0.92% | 929,734 | +40% | 0.63% | $2,854,283 |
| RENAISSANCE TECHNOLOGIES LLC | 0.89% | 902,809 | +25% | 0% | $2,771,624 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.85% | 862,839 | 0% | 0% | $2,648,916 |
| Ensign Peak Advisors, Inc | 0.62% | 626,852 | 0% | $1,924,436 | |
| CITADEL ADVISORS LLC | 0.6% | 608,267 | 0% | $1,867,380 | |
| UBS Group AG | 0.57% | 574,652 | +100% | 0% | $1,764,182 |
| NORTHERN TRUST CORP | 0.55% | 558,455 | +12% | 0% | $1,714,457 |
| FourWorld Capital Management LLC | 0.49% | 499,196 | +30% | 0.87% | $1,532,532 |
| VANGUARD FIDUCIARY TRUST CO | 0.48% | 483,060 | 0% | 0% | $1,482,994 |
| Dauntless Investment Group, LLC | 0.46% | 462,057 | 4% | $1,418,515 | |
| JANE STREET GROUP, LLC | 0.42% | 424,894 | -47% | 0% | $1,304,424 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 0.41% | 419,423 | +169% | 0% | $1,287,629 |
| JPMORGAN CHASE & CO | 0.37% | 370,177 | -4.3% | 0% | $1,047,601 |
| MARSHALL WACE, LLP | 0.34% | 342,265 | +90% | 0% | $1,050,753 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
19
Latest
Q1 2026
Rows shown
1-19 of 19
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 38,763,593 | $118,924,902 | -$478,811 | $3.07 | 115 |
| 2025 Q4 | 38,505,676 | $137,199,596 | +$13,731,282 | $3.56 | 116 |
| 2025 Q3 | 34,670,910 | $120,993,806 | +$10,399,257 | $3.49 | 107 |
| 2025 Q2 | 31,474,503 | $64,523,702 | +$31,211,552 | $2.05 | 78 |
| 2025 Q1 | 16,901,932 | $19,267,414 | +$2,727,938 | $1.14 | 42 |
| 2024 Q4 | 14,712,600 | $4,608,917 | -$2,191,797 | $0.31 | 30 |
| 2024 Q3 | 20,589,694 | $6,982,762 | +$385,704 | $0.33 | 34 |
| 2024 Q2 | 18,701,866 | $8,832,828 | -$155,334 | $0.46 | 38 |
| 2024 Q1 | 17,222,037 | $27,535,675 | -$2,492,260 | $1.58 | 44 |
| 2023 Q4 | 18,436,129 | $37,608,749 | +$6,554,810 | $2.04 | 44 |
| 2023 Q3 | 15,107,160 | $21,169,015 | +$1,157,191 | $1.40 | 36 |
| 2023 Q2 | 13,916,345 | $7,656,692 | -$4,490,020 | $0.55 | 37 |
| 2023 Q1 | 21,905,923 | $14,849,314 | -$1,309,674 | $0.68 | 37 |
| 2022 Q4 | 23,473,725 | $38,730,078 | -$1,269,944 | $1.65 | 37 |
| 2022 Q3 | 23,327,364 | $108,006,612 | +$6,672,135 | $4.63 | 39 |
| 2022 Q2 | 21,874,386 | $110,684,000 | +$2,844,383 | $5.06 | 33 |
| 2022 Q1 | 17,791,143 | $126,852,000 | -$752,294 | $7.13 | 27 |
| 2021 Q4 | 21,118,138 | $199,883,000 | +$185,679,000 | $9.75 | 21 |
| 2021 Q3 | 252,439 | $2,504,000 | +$2,504,000 | $9.92 | 1 |